LOGO
LOGO

Will Duchenne Gene Therapy Maker Sarepta Find Its Stride Again?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024 lt

A rare disease refers to a condition, disorder, or illness that impacts fewer than 200,000 people in the United States. As reported by the National Organization for Rare Disorders, there are more than 10,000 such rare diseases, collectively affecting over 30 million Americans. Over 80% of the rare diseases are said to be genetic in origin.

The stock we are bringing to your attention today is that of Sarepta Therapeutics Inc. (SRPT), which is developing treatments for some of the world's most debilitating, prevalent, and complex rare genetic diseases like Duchenne muscular dystrophy, limb-girdle muscular dystrophies, and Charcot-Marie-Tooth disease.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.

RELATED NEWS